Serine/Threonine Protein Kinase Chk1 Market Symptoms Market Research and Pipeline Review, H2 2016

'Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Pipeline Review, H2 2016', provides in depth analysis on Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

For more information about this report athttp://www.reportsweb.com/serine-threonine-protein-kinase-chk1-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1)
- The report reviews Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Request a sample copy athttp://www.reportsweb.com/inquiry&RW0001513512/sample

Table of Content

Headlines
Trends
Competitive Landscape
Prospects

Category Data

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 (Contd..1) 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by CanBas Co Ltd, H2 2016 23
Pipeline by Cascadian Therapeutics Inc, H2 2016 24
Pipeline by Eli Lilly and Company, H2 2016 25
Pipeline by Genentech Inc, H2 2016 26
Pipeline by ProNAi Therapeutics Inc, H2 2016 27
Pipeline by Sareum Holdings Plc, H2 2016 28
Pipeline by Vernalis Plc, H2 2016 29
Dormant Projects, H2 2016 46
Discontinued Products, H2 2016 47

Purchase Complete Report at http://www.reportsweb.com/buy&RW0001513512/buy/3500

Call: +1-646-491-9876
Email:sales@reportsweb.com